[go: up one dir, main page]

BR0312250A - Uso de inibidores de vasopeptidase no tratamento de nefropatia - Google Patents

Uso de inibidores de vasopeptidase no tratamento de nefropatia

Info

Publication number
BR0312250A
BR0312250A BR0312250A BR0312250A BR0312250A BR 0312250 A BR0312250 A BR 0312250A BR 0312250 A BR0312250 A BR 0312250A BR 0312250 A BR0312250 A BR 0312250A BR 0312250 A BR0312250 A BR 0312250A
Authority
BR
Brazil
Prior art keywords
diabetic
nephropathy
treatment
vasopeptidase inhibitors
vasopeptidase
Prior art date
Application number
BR0312250A
Other languages
English (en)
Inventor
Stefan Schofer
Wolfgang Linz
Markus Bleich
Jochen Huber
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0312250A publication Critical patent/BR0312250A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE INIBIDORES DE VASOPEPTIDASE NO TRATAMENTO DE NEFROPATIA". A presente invenção descreve o uso de inibidores de vasopeptidase da fórmula (I) para o tratamento e/ou profilaxia de nefropatia em pacientes diabéticos ou não-diabéticos, inclusive nefropatia diabética ou não-diabética, glomerulonefrite, esclerose glomerular, síndrome nefrótica, nefroesclerose hipertensiva, microalbuminúria ou doença renal de estágio terminal, ou resistência à insulina ou de doenças metabólicas associadas a produtos finais de glicação avançada, tal como complicações diabéticas, neuropatia diabética, nefropatia, retinopatia diabética, catarata, enfarte do miocárdio e/ou cardiomiopatia diabética ou aterosclerose ou disfunção endotelial.
BR0312250A 2002-06-28 2003-06-13 Uso de inibidores de vasopeptidase no tratamento de nefropatia BR0312250A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Publications (1)

Publication Number Publication Date
BR0312250A true BR0312250A (pt) 2005-04-26

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312250A BR0312250A (pt) 2002-06-28 2003-06-13 Uso de inibidores de vasopeptidase no tratamento de nefropatia

Country Status (38)

Country Link
US (2) US6930103B2 (pt)
EP (1) EP1519732B1 (pt)
JP (1) JP4564354B2 (pt)
KR (1) KR101072235B1 (pt)
CN (1) CN100366254C (pt)
AR (1) AR040343A1 (pt)
AT (1) ATE548040T1 (pt)
AU (1) AU2003280440B2 (pt)
BR (1) BR0312250A (pt)
CA (1) CA2490277C (pt)
CR (1) CR7667A (pt)
CY (1) CY1112905T1 (pt)
DE (1) DE10229180A1 (pt)
DK (1) DK1519732T3 (pt)
EC (1) ECSP045513A (pt)
ES (1) ES2383889T3 (pt)
HN (1) HN2003000193A (pt)
HR (1) HRP20041212B1 (pt)
IL (2) IL165935A0 (pt)
MA (1) MA27281A1 (pt)
MX (1) MXPA04012230A (pt)
NO (1) NO334811B1 (pt)
NZ (1) NZ537480A (pt)
OA (1) OA12871A (pt)
PA (1) PA8576501A1 (pt)
PE (1) PE20040582A1 (pt)
PL (1) PL218070B1 (pt)
PT (1) PT1519732E (pt)
RS (1) RS52478B (pt)
RU (1) RU2336080C2 (pt)
SI (1) SI1519732T1 (pt)
SV (1) SV2004001560A (pt)
TN (1) TNSN04262A1 (pt)
TW (1) TWI326215B (pt)
UA (1) UA82845C2 (pt)
UY (1) UY27869A1 (pt)
WO (1) WO2004002492A1 (pt)
ZA (1) ZA200409382B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP2558208B2 (ja) * 1991-03-01 1996-11-27 ゼリア新薬工業株式会社 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
EP0534363B1 (en) * 1991-09-27 1997-07-09 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
EP0625987B1 (en) * 1992-02-14 1998-04-01 Merrell Pharmaceuticals Inc. Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
CA2184696C (en) * 1994-03-24 2001-01-02 Gary A. Flynn Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
EP0835106A4 (en) * 1995-06-30 1998-09-30 Merck & Co Inc METHOD OF TREATING NEPHROPATHIES USING AN ACE INHIBITOR AND AN A II ANTAGONIST
JP3448869B2 (ja) 1995-12-27 2003-09-22 三菱ウェルファーマ株式会社 糖尿病性合併症の予防・治療剤
NZ517468A (en) * 1999-08-30 2004-02-27 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
PL209338B1 (pl) * 2001-04-12 2011-08-31 Sanofi Aventis Deutschland Pochodne merkaptoacetyloamidu, ich zastosowanie oraz kompozycja farmaceutyczna zawierająca te pochodne
US20030040509A1 (en) * 2001-08-06 2003-02-27 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ACE

Also Published As

Publication number Publication date
RU2005102087A (ru) 2005-07-10
SI1519732T1 (sl) 2012-05-31
PA8576501A1 (es) 2004-02-07
IL165935A0 (en) 2006-01-15
PL372992A1 (en) 2005-08-08
NO334811B1 (no) 2014-06-02
TW200406214A (en) 2004-05-01
ES2383889T3 (es) 2012-06-27
RU2336080C2 (ru) 2008-10-20
OA12871A (en) 2006-09-15
KR20050013642A (ko) 2005-02-04
US6930103B2 (en) 2005-08-16
MXPA04012230A (es) 2005-02-25
EP1519732A1 (en) 2005-04-06
US7514423B2 (en) 2009-04-07
TNSN04262A1 (en) 2007-03-12
KR101072235B1 (ko) 2011-10-12
MA27281A1 (fr) 2005-04-01
NO20050425L (no) 2005-01-25
HN2003000193A (es) 2004-10-27
EP1519732B1 (en) 2012-03-07
CN100366254C (zh) 2008-02-06
AR040343A1 (es) 2005-03-30
US20050171090A1 (en) 2005-08-04
AU2003280440A1 (en) 2004-01-19
UY27869A1 (es) 2003-12-31
ATE548040T1 (de) 2012-03-15
CA2490277A1 (en) 2004-01-08
CY1112905T1 (el) 2016-04-13
DK1519732T3 (da) 2012-06-18
RS100704A (sr) 2007-02-05
CA2490277C (en) 2011-11-01
PE20040582A1 (es) 2004-10-18
UA82845C2 (en) 2008-05-26
DE10229180A1 (de) 2004-01-29
NZ537480A (en) 2005-11-25
CR7667A (es) 2005-06-16
TWI326215B (en) 2010-06-21
WO2004002492A1 (en) 2004-01-08
HRP20041212A2 (en) 2005-06-30
IL165935A (en) 2010-12-30
PT1519732E (pt) 2012-05-22
ECSP045513A (es) 2005-03-10
CN1665512A (zh) 2005-09-07
JP2005533815A (ja) 2005-11-10
ZA200409382B (en) 2006-01-25
RS52478B (sr) 2013-02-28
HRP20041212B1 (hr) 2013-06-30
JP4564354B2 (ja) 2010-10-20
PL218070B1 (pl) 2014-10-31
SV2004001560A (es) 2004-02-26
US20040058911A1 (en) 2004-03-25
AU2003280440B2 (en) 2009-07-16
HK1079435A1 (zh) 2006-04-07

Similar Documents

Publication Publication Date Title
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
PH12019500961A1 (en) Combination of sglt 2 inhibitors and antidiabetic agents
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
UA95798C2 (ru) Производные циклогексилпиразоллактама как ингибиторы 11-бета-гидроксистероиддегидрогеназы 1
MXPA03000450A (es) Sulfonamidas de ciclilamina como agonistas del receptor adrenergico beta-3.
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009005048A (es) Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
TNSN08432A1 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
BR0312250A (pt) Uso de inibidores de vasopeptidase no tratamento de nefropatia
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
AR033261A1 (es) Antagonistas de nmda para el tratamiento de enfermedades adictivas
DE602005013118D1 (de) 1h-indol-3-carbonsäurederivate und deren verwendung als ppar-agonisten
WO2007054836A3 (en) 1, 2-substituted naphthalene derivatives with antiglutamatergic properties and uses thereof

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.